Topical application of .alpha.-DFMO for preventing skin cancer
US5851537A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 31, 1997 |
| Grant date | Dec 22, 1998 |
| Priority date | — |
| Expiry date | Jan 31, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/195
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A salve includes a water-miscible, hydrophilic cream vehicle, 1-22% by weight a-DFMO, and no absorption enhancer. The salve is preferably contained in an ointment tube permanently sealed at one end to preclude exposure to light and air. The salve is applied as a preventative in an appropriate amount twice daily to skin exposed to actinic radiation. An initial application of a salve including 10% by weight A-DFMO is preferred to minimize the risk of skin irritation without compromising the therapeutic value of the salve. The salve shows no systemic uptake, thereby eliminating systemic toxicities that result from other techniques for administering the drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.